Btg Dividends - BTG

Btg Dividends - BTG

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Btg Plc BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  0.00 0.0% 840.00 0.00 0.00 0.00 840.00 01:00:00
more quote information »
Industry Sector
SUPPORT SERVICES

Btg BTG Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
04/06/1998FinalGBP0.9231/03/199731/03/199813/07/199817/07/199807/08/19980.92

Top Dividend Posts

DateSubject
12/8/2019
17:55
dp1umb: BargainBob Vectura has been an absolute dog of a share for the last two or three years! I keep topping up when I think they’ve turned the corner only for them to go even lower but hopefully all the bad news is in the share price. A biotech that has definitely turned the corner is silence Therapeutics which has quadrupled in the last month and there should be more to come, but I would say is more of a gamble than vectura but the rewards should be a lot greater if all goes well. DYOR
09/12/2018
17:33
spyder: Very interesting BB. So ... Sand Grove bought 16.2m BTG shares from Woodford. Sand Grove is an ‘event driven’ hedge fund, that is to say, its strategy is to exploit valuation anomalies after a major corporate event such as a bid. Sometimes this will be an equity arbitrage if a perceived mismatch develops between the share price of the buyer and the share price of the seller, but this can’t be the case here as this is an all cash offer. That being the case, SG have spent approximately £134m to make just £1.5m or a 1.3% return. This is a tiny profit and does not reflect the risk of the deal failing to complete. I think we can draw 2 conclusions from this; 1) SG thinks the deal will definitely complete. 2) SG must be betting that another bidder will appear. Of course, they could be wrong, and their strategy will be to buy multiple bid targets and hope that one or two will receive additional offers. Their investment in Laing Infrastructure didn’t work, as this sold after just one bid, I wonder if they will have better luck with BTG?
09/12/2018
14:22
bargainbob: The parts may be greater than the sum . TIDMBTG RNS Number : 7475J Boston Scientific Corporation 07 December 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 December 2018 RECOMMENDED CASH OFFER for BTG plc ("BTG") by Bravo Bidco Limited ("Bravo Bidco") a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation ("Boston Scientific") Update on irrevocable undertaking given by Woodford Investment Management Limited ("Woodford") On 20 November 2018 the boards of Boston Scientific, Bravo Bidco and BTG announced the terms of a recommended cash offer to be made by Bravo Bidco for the entire issued and to be issued share capital of BTG at a price of 840 pence in cash per BTG Share (the "Rule 2.7 Announcement"). Defined terms in this announcement shall, except where defined in this announcement or the context requires otherwise, have the meanings given to them in the Rule 2.7 Announcement. Included in the Rule 2.7 Announcement were details of irrevocable undertakings to support the offer including that received from Woodford, which gave an irrevocable undertaking in respect of 21,253,256 BTG Shares (the "Woodford Irrevocable"). On 5 December 2018, Boston Scientific and Bravo Bidco announced that Woodford had sold: (i) 600,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Partners LLP acting in its capacity as Investment Manager of Anavio Capital Event Driven UCITS Fund; and (ii) 400,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Master Fund Limited, in each case in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Woodford has subsequently sold 16,200,000 BTG Shares which were subject to the Woodford Irrevocable (the "Transferred Shares") to Sand Grove Capital Management LLP acting in its capacity as discretionary investment manager on behalf of Sand Grove Opportunities Master Fund Ltd, Sand Grove Tactical Fund LP and Investment Opportunities SPC for the account of Investment Opportunities 2 Segregated Portfolio ("Sand Grove"), in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Therefore, Sand Grove has provided an irrevocable undertaking (the "Sand Grove Irrevocable") on substantially the same terms as the Woodford Irrevocable in respect of the Transferred Shares, save that the provisions in the Woodford Irrevocable permitting transfer of BTG Shares in circumstances, other than to the extent required by law, are not contained in the Sand Grove Irrevocable. The total number of BTG Shares which is subject to irrevocable undertakings to support the offer remains unchanged. The Sand Grove Irrevocable (as well as a copy of this announcement) will be uploaded to the Boston Scientific website (hxxp://investors.bostonscientific.com/) shortly. Enquiries: Bravo Bidco / Boston Scientific +1 (508) 683-5565 Susie Lisa (Investor Relations) Barclays Bank PLC, acting through its +44 (0) 20 7623 2323 Investment Bank (financial adviser to Bravo Bidco and Boston Scientific) Douglas Solomon Jed Brody Derek Shakespeare Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Boston Scientific and Bravo Bidco and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Boston Scientific and Bravo Bidco for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement. This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation, inducement or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of or exercise rights in respect of any securities, or the solicitation of any vote or approval of an offer to buy securities in any jurisdiction, pursuant to the Acquisition or otherwise nor shall there be any sale, issuance or transfer of any securities pursuant to the Acquisition in any jurisdiction in contravention of any applicable laws. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or in the event that the Acquisition is to be implemented by means of a Takeover Offer, the Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any decision, vote or other response in respect of the Acquisition should be made only on the basis of information contained in the Scheme Document. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched. This announcement does not constitute a prospectus or prospectus-equivalent document. This announcement has been prepared for the purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom. In accordance with the Code, normal United Kingdom market practice and Rule 14e-5(b) of the Exchange Act, Barclays and its affiliates will continue to act as an exempt principal trader in BTG securities on the London Stock Exchange. The purchases and activities by exempt principal traders which are required to be made public in the United Kingdom pursuant to the Code will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website at www.londonstockexchange.com. This information will also be publicly disclosed in the US to the extent that such information is made public in the United Kingdom. Disclosure requirements of the Code In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at hxxp://investors.bostonscientific.com/, by no later than 12 noon (London time) on 10 December 2018. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END OUPUNVRRWBAURUA (END) Dow Jones Newswires December 07, 2018 02:00 ET (07:00 GMT)
16/11/2018
11:50
a1ord53: I think that news in October were better than on 13 th of November and share price moved down. And last week and on 13 th share price were like always manipulated.Its why it going back to reality 5-6 £ range. RBC again issued underperform with target price 490 p Varithena value negative CroFab is going to loose 70% revenues due to price reduction Zytiga will halved income Beads no growth anymore according dame Louise( she said growth with market) Who sold at 690-670!should feel very lucky I read transcript of meeting with analysts and answers of dame and cfo were not precise - more likely than concrete.
15/11/2018
10:58
dp1umb: Why can’t investing be more simple? Positive news = change of momentum = rise in share price. Simple!
11/11/2018
18:11
bargainbob: What to compare on Tuesday. 4 October 2018 | 09:45am StockMarketWire.com - Healthcare company BTG guided product sales higher Thursday after including its varicose vein treatment Varithena in its oncology and vascular portfolio. The company said it expected product sales for the combined portfolio to grow by 15%-to-17% this year, up from its previous forecast of 13%-to-15%. In pharmaceuticals, following a good first half, BTG said it expected full-year sales to be around the upper end of the guidance range of flat-to-single digit decline. A better-than-expected first-half performance in pharmaceuticals was driven by DigiFab and Voraxaze, and a good performance from CroFab, BTG said. First-half product sales growth was driven by 'good' performance in Interventional Medicine led by strong growth in radiotherapy treatment TheraSphere and the cryoablation products, the company said. Varithena was expected to become profitable during the 2019/20 financial year with sales expected to peak in the high tens of millions of dollars. Varithena sales would be included within the Vascular product sales line going forwards, BTG said. The company also announced that Chairman Garry Watts was set to retire. At 9:45am: [LON:BTG] BTG PLC share price was +31p at 590.5p Story provided by StockMarketWire.com
27/10/2018
12:36
spyder: I don’t think anyone expected J&J to win the patent case and as txi mentions, it was always assumed that a favourable outcome would be a (BIG!) bonus, but the default position was a 31.10.18 expiry. On that basis, the share price on Monday should not be affected, but sentiment probably dictates otherwise. It is curious that J&J still feels so strongly about appealing the decision, but I guess it might be a case of “they would say that wouldn’t they”.
25/7/2018
08:18
spyder: This is a welcome respite although I wouldn’t get too excited at this stage as, given the time of the year, it seems to me very unlikely that anyone would launch a bid at the beginning of August. As also noted above, clearly he Board had no clue given the recent shares purchase. This could just be a ‘silly season’ Pump and Dump rumour OR I suppose there could be something in it? Looking at the share price action yesterday, it seems clear that the story came out of the US (home of the Pump and Dump!) but, but, but, if there is ever a bidder, they are much more likely to come from the US than anywhere else, and as pointed out above, they will strike when the £/$ exchange rate is low, and when the UK market undervalues the company’s prospects, which it is presently doing - massively. I suspect there are a few companies out there watching... possibly even including J&J?? If they were optimistic about a long term revenue stream from Zytiga, they could buy BTG, close out the royalty stream and sell on the rest - simple but effective arbitrage ...
25/7/2018
07:42
bargainbob: One of Britain’s most prominent healthcare companies shot to the top of the FTSE 250 amid speculation that it was being considered a takeover target. BTG closed up 6.7 per cent, or 33¼p, at 529½p as rumours spread of preparations for a bid. The company’s share price has tumbled by 30 per cent since the start of the year, a fall that accelerated amid reports of a £102.8 million operating loss for the year to the end of March. BTG took a £144.7 million charge after delays with Pneumrx, its emphysema treatment, which subsequently failed to win backing from a key panel of the US Food and Drug Administration.
23/9/2017
10:22
bargainbob: From Dave on eye eye eye Im SORRY but my last post should not have been posted, as it wasn’t finished, I must have hit the wrong button before leaving my computer this morning. ---- --------------------------------------------------------------------------------- Reading the judgement posted here on the BB it makes my blood boil ,to read BTG were first approached by wellstadt with their suspicions many years ago but instead of talking to wellstadt, our management decided to instigated a breach of contract law suit against wellstadt instead ,now had the management agreed back then to return to the terms of that agreement ,then none of this would have happened ,and we would still be selling a licenced product for profit. How mad is that ?. I know from my own experience ,the last thing you do is attack a customer ,or a company you are working with, unless your 100% confident they had done something wrong, and that you could prove in a court of law and after talking to the company, to see if you could iron out the difficulties amicably ,but it appears in this case, BTG didn't do that ,and that to me ,that is asking for trouble. What's even more concerning about this, is that control of the sales & marketing budgets were changed after the agreement was signed, and would be detrimental to the launch of wellstedt product, and would break the terms of our contract with wellstadt, yet nobody at BTG saw this as a problem . To me all of this could have been avoided, had the BOD listened to Wellstads grievances in 2015. Had they done that ,then we wouldn’t be losing a product that could have made BTG a very good profit over many years, and for what is said to have been a very little amount of outlay according to the trial notes, and that to me is unforgivable, how this will play out with other clients, or with future clients ,I just don’t know, but as we all know 50% of business is about trust ,and if you lose that in the USA , then you are finished as most medical products in the U.S.A are purchased through a medical insurance syndicate . This whole sorry business shows how bad our marketing has been over the years, it could also explain why other BTG products we have launched in the USA, have also failed to meet expectations, or their growth predictions over the years ,and is something I, and many other posters on this BB have queried on several occasions , well maybe now we have the answer to all those questions ,as It seems to me, BTG either have a poor sales &marketing dept ,or B.T.G, lack the experience in the top echelons of the company, when it comes to sales &marketing . I know from my own experience in manufacturing and retail that most companies in UK today employ professional sales and marketing people ,as they know how to support a team of sales people and also know how to distribute a sales team across an area in order to maximise sales, they are also aware of the importance of marketing when launching a new product ,it’s their expertise of the market that is key to the success or failure of a product ,so if ,but if our management team can’t do that with in a set budget then heads should roll, I also believe ,that any shares received by the BOD through the BTG share initiative, should now be returned/or the cash repaid to the company, as they obviously failed in their responsibilities to the protect B.T.G shareholders profits, and the good name of the company ,But had the BOD acted upon wellstadt complaint back in 2015 things might be different now . Obviously we will never know the full story of what happened, or who was to blame for this mess ,but this sorry tale could have been soughed out amicably in 2015, and hopefully it still can be, as the judge has given both parties 21 days to find a settlement before ordering costs and payment . BE HAPPY DAVE ..
Your Recent History
LSE
BTG
Btg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 02:23:07